Lunit (KRX:328130), a provider of AI for cancer diagnostics and therapeutics, announced on Monday that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place 30 May-3 June in Chicago, IL.

One of studies, conducted with Japan's National Cancer Center Hospital East (NCCE), evaluated HER2 expression in biliary tract cancer (BTC) patients using Lunit's AI-powered analyzer. The resulting AI scores showed strong agreement with pathologist-assigned IHC scores in a 288-patient screening cohort.

The company will also present a study conducted with NCCE evaluating concordance between pathologist- and AI-assessed PD-L1 expression in lung cancer patients enrolled in LC-SCRUM, one of Japan's largest nationwide observational cohorts, using Lunit SCOPE PD-L1, while another will cover an AI model to predict CLDN18.2 expression in gastric cancer.